RSS Feed – HDBuzz

  • Finding the silver lining: an update on the Roche GENERATION-HD1 trial data
    On January 20th, Roche shared a set of long-awaited data from the GENERATION-HD1 trial of tominersen, a huntingtin-lowering drug. Although the trial did not meet its key goals, and too-frequent dosing may even have made patients worse, new findings have given us some cause to hope that tominersen could still ... read more
    Source: HDBuzzPublished on 2022-01-21
  • KINECT-HD trial shows valbenazine improves involuntary movements in Huntington's disease
    Chorea -- unwanted fidgety or jerky movements -- is one of the most noticeable features of Huntington's disease (HD). There are already drugs to treat chorea licensed specifically for use in HD, as well as so-called off-label treatment options. But all the existing treatments have potential downsides, so new drugs ... read more
    Source: HDBuzzPublished on 2021-12-14
  • “Seeing” the toxic huntingtin protein in people with HD
    Scientists have developed a tool which allows us to “see” the toxic clumps of the huntingtin protein using special scanners. People with Huntington’s disease (HD) make a toxic form of the huntingtin protein which forms clumps in cells of their bodies, which accumulate during HD progression. Tracking how these clumps ... read more
    Source: HDBuzzPublished on 2021-12-07
  • Updates from the EHDN Meeting 2021
    Last month, the Huntington’s disease (HD) research community, patients and other stakeholders met online at the European Huntington’s disease network (EHDN) conference. Despite the ongoing global pandemic, there is a tremendous amount of work underway in labs and clinics around the world as researchers continue to better understand HD and ... read more
    Source: HDBuzzPublished on 2021-10-28